Alzheimer's Disease, Obesity
Conditions
Brief summary
The purpose of this study is to compare average methylation of epigenetic markers on genomic DNA and some genes (APP, BACE, LRP, SorL1) involved in cerebral amyloid homeostasis: * Of obese young adults and healthy young adults * Of obese young adults and individuals affected by Alzheimer's disease (AD) having been obese at young adult age (\<50 years old) or individuals affected by Alzheimer's disease (AD) having never been obese. The secondary purpose is to determine if there is an association between the frequency of these epigenetic markers and elements associated to the metabolic syndrome (lipidic and glycemic analysis, leptinemia, inflammation markers) and clinical ones (visceral fat mass, body mass index) in young adults.
Interventions
PROCEDUREBlood sample
Sponsors
Central Hospital, Nancy, France
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Group 1: * 18-50 year old women, age- (10 years) and sociocultural-matched with group 2 * Non obese and never been obese * 18.5 \< BMI \< 25 * Folstein MMS \> 27 * Informed consent * Affiliation to social security plan Group 2: * 18-50 year old women, age- (10 years) and sociocultural-matched with group 1 * Waist size \> 88cm * 30 \< BMI \< 45 * Insulin-resistant patients (Insulin resistance index, HOMA-IR \> 3.8) * Obesity onset during childhood (pre-puberty period) * Folstein MMS \> 27 * Informed consent * Affiliation to social security plan Group 3: * \>60 year old women, age- (10 years) matched with group 4 * No obesity history (18.5 ≤ BMI \< 25 at adult age) * Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic process according to new recommendations of 2011 of National Institute on Aging and Alzheimer's Association on diagnostic guidelines for Alzheimer's disease * 15\< Folstein MMS ≤ 26 * Informed consent * Affiliation to social security plan Group 4: * \>60 year old women, age- (10 years) matched with group 3 * Obesity history (BMI \> 30 at least one time at adult age) * Sporadic forms of mild to moderate AD with demonstration of AD physiopathologic process according to new recommendations of 2011 of National Institute on Aging and Alzheimer's Association on diagnostic guidelines for Alzheimer's disease * 15 \< Folstein MMS ≤ 26 * Informed consent * Affiliation to social security plan
Exclusion criteria
Group 1: * \<18 * Patient under guardianship, curatorship or judicial protection * Folate supplementation * Diabetic or glucose intolerant subjects * Present participation to another study with neuropsychological evaluation and/or drug administration * Pregnant women Groups 2,3 and 4: * \<18 * Patient under guardianship, curatorship or judicial protection * Folate supplementation * Present participation to another study with neuropsychological evaluation and/or drug administration Group 2: \- Pregnant women Group 4: \- Obese or overweight patients (BMI\>25)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Methylation of CpG islands in genomic DNA and in 4 target genes involved in AD (APP, SorLA/LR11, BACE1, LRP) in obese and AD subjects | day 0 |
Secondary
| Measure | Time frame |
|---|---|
| visceral fat mass level | day 0 |
| leptinemia by ELISA | day 0 |
| insulinemia by ELISA | day 0 |
| body mass index | day 0 |
| triglyceridemia | day 0 |
| HDL cholesterol level in blood | day 0 |
| Reactive C protein level in blood | day 0 |
| glycemia | day 0 |
Countries
France
Contacts
Primary ContactThérèse RIVASSEAU-JONVEAUX, Dr
Outcome results
None listed